To The Moon

$Vaxcyte, Inc.(PCVX)$ $Madrigal Pharmaceuticals(MDGL)$ 💉💊📈🅱️ U͎ L͎ L͎ I͎ S͎ H͎💊💉

🚀 Biotech’s Big Bet, Vaxcyte ($PCVX), Madrigal ($MDGL) & 2025’s Healthcare Boom

Markets are a pressure cooker in March 2025, with 10-year Treasury yields creeping toward 4.2%, PMI data flashing manufacturing weakness, and tariff threats rattling equities. Yet, Goldman Sachs’ David Kostin is doubling down on healthcare, a sector that has outperformed the S&P 500 by 7 points YTD while still trading at an 18% P/E discount, the widest in 20 years.

With healthcare powering 17% of US GDP, it is the perfect defensive, offensive hybrid. That is why I am zooming in on two biotech powerhouses backed by Goldman Sachs.

✅ Vaxcyte ($PCVX), disrupting vaccines with synthetic biology

✅ Madrigal ($MDGL), dominating the first, ever NASH treatment market

One of these has my attention for 2025, but which one wins the biotech showdown?

🔬 Vaxcyte Inc. ($PCVX), The Vaccine Disruptor Poised to Break Out

💡 The Edge

Vaxcyte’s cell, free protein synthesis platform is a biotech battering ram, engineering next, gen bacterial vaccines with superior precision and immunogenicity. Its potential? Disrupting the $10B+ pneumococcal vaccine market, currently owned by Pfizer’s Prevnar 20.

📌 Pipeline Highlights

   •   VAX, 31, leading pneumococcal conjugate vaccine (PCV), with Phase 3 trials launching mid, 2025 and topline data due 2026

   •   VAX, 24, Phase 2 trials for infant protection, with data expected Q1 2025

   •   Preclinical Targets, Group A Strep (800M cases), Shigella (600K deaths), Periodontitis (affecting 65M US adults)

💰 Cash Reserves, $3.1B (as of Dec 2024), ensuring years of R&D runway with zero dilution concerns

📢 Real, Time Market Buzz (7 Mar 2025)

   •   Social media sentiment analysis, 70% bullish chatter on VAX, 31’s Phase 3 preparation, with “Pfizer killer” trending

   •   Hedge funds and institutions are piling in, seeing this as a multi, bagger opportunity

📊 Analyst Sentiment & Forecasts

   •   Goldman Sachs’ Chris Shibutani, Buy rating, $138 price target (87% upside from $73.89)

   •   Street Consensus, 7/7 Strong Buy, $149.43 avg PT (102% upside)

   •   Hedge Fund Moves, Institutional ownership surged to 92% in Q4 2024, with FMR LLC adding 1.2M shares

🔥 Why It’s Hot

If VAX, 31 captures 60, 70% of the pneumococcal vaccine market, this stock is not just a buy, it is a moonshot.

💊 Madrigal Pharmaceuticals ($MDGL), The NASH Leader Printing Cash

💡 The Play

Madrigal made history in 2024 by launching Rezdiffra™, the first, ever FDA, approved treatment for non, alcoholic steatohepatitis (NASH). This is a $35B+ market with zero prior treatment options.

📌 Recent Earnings & Adoption

   •   Q4 2024 Sales, $103.3M from Rezdiffra™ alone

   •   Total 2024 Revenue, $180.1M (from zero the prior year!)

   •   11,800+ patients already prescribed the drug

📢 Real, Time Market Buzz (7 Mar 2025)

   •   Q4 earnings crushed expectations, Stock rallied 20% to $372.26

   •   Social media sentiment, 80% positive post, Q4 earnings, though some caution on 2027 competition risks

📊 Analyst Sentiment & Forecasts

   •   Goldman Sachs’ Andrea Newkirk, Buy rating, $539 price target (55% upside from $347.28)

   •   Street Consensus, 14/15 Buy, $413.87 avg PT (20.71% upside)

   •   Hedge Fund Moves, Biotech hedge funds raised stakes 15% in Q4, betting on continued revenue expansion

🔥 Why It’s Hot

Madrigal owns the NASH market, for now. But with competition coming by 2027, they will need to scale fast before rivals hit.

📊 The Face, Off, PCVX vs. MDGL

Both stocks have strong tailwinds, but their risk, reward profiles differ significantly.

📌 Vaxcyte ($PCVX) offers high, growth potential with its next, gen vaccine platform, targeting a $10B+ market with limited competition. The key catalyst is its Phase 3 trial launch in mid, 2025, which could unlock massive valuation upside. Hedge funds have aggressively accumulated shares, with institutional ownership hitting 92% in Q4 2024. Analysts see 100%+ upside, making it a high, risk, high, reward play.

📌 Madrigal ($MDGL) is a revenue, generating powerhouse thanks to Rezdiffra™, the first, ever FDA, approved NASH treatment. The company posted $180M in sales in 2024, with over 11,800 patients already on treatment. The short, term outlook is strong, but competition from Novo Nordisk could emerge by 2027. With a 20% upside forecast, Madrigal is a lower, risk, steady gainer compared to Vaxcyte.

💡 Institutional investors love Vaxcyte’s explosive upside, while Madrigal provides more stable, predictable returns. The choice depends on whether you want a potential multi, bagger or a safer biotech winner.

🎯 My Call, Why Vaxcyte ($PCVX) Is My Top Watchlist Stock 👀

Madrigal’s Rezdiffra™ launch is a massive success, and the stock offers steady gains. But Vaxcyte has a breakout catalyst brewing.

📌 100%+ upside from analyst targets

📌 Phase 3 trials in mid, 2025 could unlock parabolic growth

📌 A potential $10B market opportunity with limited competitors

🚀 If Vaxcyte’s Phase 3 trials succeed, this stock could 3x by 2027.

🤖@TigerGPT, with Vaxcyte’s 92% institutional accumulation and Madrigal’s projected $600M+ sales path, which of these two stocks has the superior risk, reward profile for a 3, year biotech hold?

📢 Please Like, Repost, and Follow me for sharp setups, stock trends, and actionable insights 🚀📈 I am all about spotting the next movers and sharing strategies that deliver results! Let’s trade smarter and grow together! 🍀🍀🍀

Happy trading ahead. Cheers, BC 📈🚀🍀🍀🍀

@Tiger_comments @TigerPicks @TigerStars @TigerWire @Daily_Discussion